Background
Transplant recipients require life-long immunosuppressant therapy to treat and prevent rejection events that would otherwise jeopardise the performance and longevity of their newly acquired graft [1, 2] . Immunosuppressant medicines are used in 3 treatment stages; induction, as maintenance therapy and for acute treatment of organ rejection [3] . Community costs are highest for long-term maintenance immunosuppressant therapy, following hospital discharge after transplantation [4] . The kidney is the most common solid organ transplanted; in Australia over 9000 people currently live with a functioning kidney allograft, with over 800 further kidney transplant operations per annum [5] . Increasing rates of utilization and expenditure on immunosuppressants present a worldwide challenge.
Advances in maintenance immunosuppression have led to reductions in acute rejection rates and improvements to shortterm patient survival over the past 2 decades [6, 7] . In contrast, the evaluation of long-term graft survival has been difficult to interpret with contradictory data being reported [8] [9] [10] . The goal of maintenance immunosuppressant therapy is to maximize long-term allograft survival while minimizing acute rejection, drug toxicity and over-immunosuppression leading to infections and certain types of cancer [11] . The immunosuppressant agents, mycophenolic acid, tacrolimus, cyclosporin, sirolimus and everolimus, used in various combinations, often with corticosteroids (prednisone or prednisolone), form the basis of contemporary maintenance therapy for transplant recipients [11, 12] . Each of these agents receives public subsidy in Australia through the national Pharmaceutical Benefits Scheme (PBS) for the prevention and/or treatment of renal allograft rejection following transplantation, while some are also subsidized for other less commonly transplanted organs or for the management of certain autoimmune conditions [13] . Dispensing of these medicines is also publically subsidized in Northern European countries such as Norway, Denmark, Sweden, and the Netherlands. With reasonably similar economic conditions, health care systems and scope of prescribing, these 5 countries prove good comparison data for international pharmacoepidemiologic research.
To date, there has only been a single paper investigating the epidemiology and economics associated with usage of maintenance immunosuppression in Australia [14] . This 2009 study compared mycophenolic acid utilization in Australia and Northern Europe to develop a rational baseline for projections of future utilization and costs [14] .
The aim of the present study is to examine the utilization of mycophenolic acid, tacrolimus, cyclosporin, sirolimus and everolimus in Australian transplant recipients, and to compare and contrast Australian data with the publically subsidized utilization data from Norwegian, Swedish, Danish, and the Netherlands.
Material and Methods

Data source
Australian records relating to PBS dispensing and expenditure were collected from the administrative database, Medicare Australia Item Statistics [15] . Specific item codes associated with the various forms, strengths and types of subsidy for each studied drug (Appendix 1) were entered into the database and a utilization report generated providing the number and cost of PBS prescriptions dispensed per month between 2007 and 2013 [13] . Due to division in state and federal government responsibilities in health care provision and changes in funding models over the study period, all hospital utilization and expenditure information prior to 2014 were not fully characterized using PBS item statistics alone [13, 15] . To capture hospital-specific utilization and expenditure, the highly specialized drug (HSD) national expenditure reports (public and private hospitals) [16, 17] were used. Mid-year data on population in Australia were obtained from the Australian Bureau of Statistics [18] . Data on utilization for each immunosuppressant in Norway, Denmark, Sweden and the Netherlands were obtained from their respective healthcare databases [19] [20] [21] [22] . Data in these archives were available as either daily defined dose (DDD) or DDD/1000 population/day [23] . Mid-year data on population size in each of these countries were obtained from their respective government databases [24] [25] [26] [27] . Australian, Norwegian, Danish, and the Netherlands immunosuppressant utilization data were obtained from both the community and hospital settings. Swedish data were only available for community pharmacy dispensing.
Information relating to all allograft transplant operations performed per year, number of renal transplants currently functional in the community and rates of renal transplantation per million population was gathered from Australian Transplant Registries [5, 28, 29] while international renal transplantation figures were obtained from the International Registry of Organ Donation and Transplantation (IRODaT) maintained on behalf of Scanditransplant and Eurotransplant [30] .
Data analysis
Australian PBS and HSD data relating to the utilization of mycophenolic acid, tacrolimus, cyclosporin, sirolimus and everolimus were collated as number of prescriptions dispensed per month from 2007 to 2013. To allow international comparison and analysis these data were converted to DDDs. The DDD (2014) for mycophenolate mofetil was 2000mg, tacrolimus 5 mg, cyclosporin 250 mg, sirolimus 3 mg and everolimus 1.5 mg [23] . The DDD for mycophenolate was listed as the mofetil salt and to adjust this to enable aggregation of all different salt forms as mycophenolic acid this was multiplied by 0.739 (DDD for mycophenolic acid 1478mg). DDD for all formulations for each drug were then added together. DDD/1000 population/day was calculated for each year. In short, the number of dispensings was multiplied by the pack size and strength of each individual dosage form (tablet, capsule and suspension) to obtain total milligrams per year. Milligram per year were then divided by the DDD for each immunosuppressant and finally divided by the Australian population, in thousands, and multiplied by the number of days in each respective year. A similar process was applied to HSD reporting where information on the number of dispensings per quarter for each specific PBS item code was available between 2007 and 2013. These were multiplied by pack size and strength, divided by appropriate DDD and finally adjusted for population size and days in a year. In both PBS and HSD databases, data relating to the use of mycophenolate sodium for use in lupus nephritis, recognized by separate item numbers, were excluded to enable transplantationspecific utilization to be calculated.
To calculate the total DDD/1000 population/day for each immunosuppressant in Australia, both PBS and HSD sources were summed. Because of the ongoing changes to hospital and public subsidy over the study period, the PBS utilization data were corrected to exclude all hospital HSD-related PBS item codes, as these were already captured by HSD reporting. This ensured no "double counting" in the overall results. Total expenditure was calculated similarly to utilization. PBS and HSD reporting were summated, again removing HSD-related PBS item codes from PBS item statistic reports to avoid "double counting". When considering the specific formulations of mycophenolic acid and tacrolimus individually, utilization of enteric-coated mycophenolate sodium increased from approximately 18% of total mycophenolic acid consumption in 2007 to 27% of total mycophenolic acid consumption in 2013, taking market share from the mycophenolate mofetil formulation. Similarly usage of extended-release tacrolimus, first dispensed in December 2010, has grown continually such that it now accounts for 10% of the total tacrolimus consumption in 2013.
Dispensing and provision of these 5 medicines in Australia can be through community pharmacies or public and private hospitals. Between 2007 and 2013 approximately 25% of total supply was via community pharmacies, through general public subsidization, while 70% and 5% was via public and private hospitals, respectively, through the HSD scheme. , rising usage of mycophenolic acid, tacrolimus and everolimus, falling usage of cyclosporin and sirolimus) while Norwegian utilization was consistently higher than the other 4 countries. In 2013, utilization of mycophenolate, tacrolimus and cyclosporin was significantly higher for each European country compared to Australia (Chi-squared analyses; p<0.001 for each medication). While sirolimus and everolimus use was lower in Australia compared to each European country, these differences were not statistically significant. Australian utilization (all 5 medications combined) was found to be growing faster than Denmark, at similar rates to Sweden and the Netherlands and slower than Norway (0.009, 0.005, 0.009, 0.009 and 0.01 DDD/1000 population/day per year, respectively). Overall Australian utilization was growing slightly faster than total Northern European utilization (0.009 verses 0.007 DDD/1000 population/day per year). Kidney transplantation accounted for 61% of all solid organs transplanted in Australia in 2012 while liver, lung, heart and pancreas transplantation contributed 19%, 11%, 6% and 2%, respectively [5, 28, 29] . Figure 4 shows the number of renal transplant operations per million population and the number of people living with a functioning renal allograft between 1991 and 2012 in Australia. The rates of both have continually increased over this period. with 60 and 57.5, respectively, compared to Australia, Denmark and Sweden with 36.7, 37.6 and 41.8, respectively.
Sensitivity analyses showed inclusion of PBS item codes pertaining to the use of mycophenolate in lupus nephritis (Appendix 1) increased overall Australian utilization figures by 2% whereas using the DDD for the mofetil salt of mycophenolate, rather than the corrected DDD for mycophenolic acid contributed a 9% drop.
Discussion
This study for the first time documents the increasing use of maintenance immunosuppressive medications, contrasting different countries which have publicly funded subsidy for these medications. Immunosuppressant usage and subsequent expenditure are rising in Australia and Northern Europe. The number of transplant operations performed each year and the number of people living with a functioning renal allograft in the community is rising. With the current ageing population [32, 33] and increasing rates of hypertension and type II diabetes [32] ; new techniques such as ABO incompatible live donor transplantation and HLA desensitization providing avenues to increase organ availability [34, 35] ; and improvements in post-transplant care it is expected that the number of people requiring a transplant and those living with a functional allograft will continue increasing into the future. This will have future implications for the pharmaceutical budgets of these countries.
All the Northern European countries in this study had higher utilization of the maintenance immunosuppressant medications than Australia. Australia has an opt-in system for organ donation requiring citizens to nominate themselves as organ donors [34] . Internationally, The Netherlands and Denmark have a similar opt-in system [30] but both still have higher rates of transplantation than Australia [30] . Norway and Sweden have an opt-out system for organ donation and everybody is considered as a potential organ donor unless they specify otherwise [30] . These differing policies may be one of the underlying factors contributing to the larger number of transplants per head of population in these countries compared to Australia, and hence higher immunosuppressant use. The specific patterns of utilization in Australia and Northern Europe show that mycophenolic acid, tacrolimus and everolimus utilization had an increasing and steady uptake. This practice is supported by literature evidence that a mycophenolic acid/tacrolimus regimen offers patients an increased length and quality of life when compared to the previously common azathioprine/cyclosporine regimen [11] . As tacrolimus can cause nephrotoxicity and subsequent rejection, everolimus substitution has shown promise as an alternative for the long-term management of rejection combined with mycophenolic acid [36] . Everolimus substitution is considered most clinically appropriate between 12 and 72 months post-transplant [37] [38] [39] [40] . This evidence aligns well with the observed results and provides insight into the evolving practice of prescribers being shaped by the current literature. Similarly, cyclosporin and sirolimus utilization is decreasing, also supported by current evidence. Tacrolimus has been identified as a clinically and pharmacoeconomically superior calcineurin inhibitor thus a majority of new transplant recipients should receive tacrolimus [41] . Nevertheless there are no data to suggest that switching from cyclosporin to tacrolimus after stabilization has benefits on long-term outcomes so patients already stabilized on cyclosporin generally remain on it [42] [43] [44] . This is consistent with utilization patterns seen in this study, with cyclosporin utilization decreasing gradually over time, not dropping off completely. Sirolimus appears to be in a similar situation as everolimus use has been shown to be clinically non-inferior with a more tolerable side effect profile and it appears to be the preferred mammalian target of rapamycin inhibitor (mTOR) [37] .
Australian utilization was significantly lower for mycophenolate, tacrolimus, and cyclosporin compared to the 4 European nations (P<0.001). Linear regression, investigating changes over time, showed Australian utilization of these 5 medications growing at a slightly faster rate than total Northern European utilization. Using Northern European utilization as a projection for growth, it is postulated that Australia is lagging by roughly 5 years, probably due to lower transplant rates [30, 45] ; i.e., Australian utilization in 2013 is comparable to Northern European utilization in around 2008. Australia has had many public campaigns to try to increase organ donation [46] . With the potential for growth, Australia could bridge the gap with Northern Europe in future years, and it is important that it is realized that entails an increase in overall government expenditure probably in line with that experienced in recent years in Northern European countries.
Australian government expenditure on maintenance immunosuppressants has already climbed rapidly to almost AUD$100 million in 2013. Similar to utilization, government expenditure on mycophenolic acid, tacrolimus and everolimus increased over the study period. The opposite was recorded for cyclosporin and sirolimus. Several initiatives recently enacted by the Australian government, as well as cheaper generic availability of pharmaceuticals after patent expiry, have introduced cost-savings measures and these introduce uncertainty about future pricing structures and PBS expenditures. However, by considering the increasing number of kidney transplant operations, functioning kidney transplants in the community and potential for widening of the subsidized indications, particularly for mycophenolate [47] [48] [49] , tacrolimus [50] and everolimus [51] [52] [53] , immunosuppressant expenditure will continue to rise into the future. It is not likely that generic formulations 
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will decrease costs by the amount needed to offset increased utilization. It is also important to consider the wider scope of health expenditure, not just the government outlay on prescription medicines. Tacrolimus has been demonstrated to be a cost-effective option compared to cyclosporin and although a more expensive drug in direct costs, indirect cost-savings such as reduced hospital stay, longer graft functioning and improved patient quality of life provide benefits [54] [55] [56] . Similarly, mTOR introduction to the immunosuppressive regime through substitution or minimization strategies, although expensive, has been estimated to provide a cost-saving role to the overall treatment of these patients [36] . It is through pharmacoeconomic analysis the true price of these medicines can be understood and displayed in a holistic manner not just with a focus on drug acquisition costs [57] .
This study did not include other therapies used in the management of rejection in renal transplant patients including azathioprine, corticosteroids and the biological monoclonal antibodies. Azathioprine has now been largely replaced by mycophenolic acid in maintenance regimens and is mainly used for indications other than rejection prevention [5] . Similarly usage of oral corticosteroids (prednis(ol)one) in transplant recipients specifically cannot be identified in the PBS database as these agents have numerous subsidized indications, all sharing the same PBS item code, and cost of these medicines falls below the PBS co-payment. Biological monoclonal antibodies are very costly treatments sometimes used for induction therapy and the treatment of acute rejection. These agents are not included in long-term maintenance immunosuppressant regimens and thus were not included.
The data relate primarily to kidney transplantation, although use of immunosuppressants in other transplant groups was included to a lesser extent. Kidney transplantation accounted for 61% of all the solid organ transplants in Australia in 2012. Mycophenolate is subsidized by the PBS for the use in cardiac and renal transplantation, tacrolimus for all transplants, cyclosporin for all transplants, sirolimus for cardiac and renal and everolimus for only renal (Appendix 1). The next highest transplant group after renal transplant recipients was liver recipients (19% in 2012), but only tacrolimus and cyclosporin receive subsidy for this indication.
The Australian PBS administrative database primarily documents dispensing of publicly subsidized medicines for the purposes of reimbursement and expenditure analysis. This provides several limitations for research including the assumption that each recorded dispensing was the maximum PBS subsidized quantity. It was also assumed that all use of these medicines was publically subsidized. Private prescription use however is likely to be vanishingly small due to the extremely high prices of these medicines and the ready accessibility of public subsidy for all Australian residents. Transplant recipients requiring rejection prophylaxis fulfil the subsidy restrictions to receive these medicines for a low price.
Sensitivity analyses were conducted to consider the potential impact if mycophenolic acid data pertaining to lupus nephritis use were included in Northern European data (whereas they are separated in Australian data). Inclusion of this information together with the data for transplantation only contributed another 2% to the overall mycophenolic acid utilization in Australia, therefore was not likely to make a major difference if this use was included in Northern Europe. This study assumed that international reporting of mycophenolic acid DDDs and DDD/1000 population/day incorporated the mofetil salt correction factor of 0.739. As it is difficult to ascertain whether these databases accounted for this correction or not, further sensitivity analyses were conducted to assess the impact this would have on results. Sensitivity analyses show that by using the DDD for mycophenolate of 2000mg instead of 1478mg, even the 9% higher apparent utilization which would have resulted would not have been sufficient to explain the difference between Australian and Northern European usage.
Conclusions
There is an increasingly large number of Australians receiving kidney transplant for which they are required to take various combinations of mycophenolic acid, tacrolimus, cyclosporin, sirolimus, and everolimus for the remainder of their lives. Because of this, immunosuppressant utilization and expenditure is rising in Australia. Internationally, this study found significant differences between the utilization of the 5 medicines in Australia and Northern Europe. Trends in utilization were considered and with the growth potential predicted from Northern Europe it can be expected that these medicines will continue consuming an increasing share of Australian pharmaceutical expenditure in years to come. The 5 studied immunosuppressants (mycophenolic acid, tacrolimus, cyclosporin, sirolimus, and everolimus) are high-cost, life-preserving drugs; increasing utilization and expenditure have increased the financial impact felt by Australian and international pharmaceutical budgets.
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